A year in pharma and biotech R&D: No meltdown fears for pharma's R&D productivity
This article was originally published in Scrip
Executive Summary
The pharmaceutical research enterprise shows an encouraging bias towards progress rather than failure. Even discontinued projects provide a window on the value opportunities of the future, writes Christopher Bowe.